Specialized proresolving mediators in infection and lung injury.
Anti-Inflammatory Agents
/ therapeutic use
COVID-19
/ metabolism
Docosahexaenoic Acids
/ therapeutic use
Herpes Simplex
/ drug therapy
Humans
Influenza, Human
/ drug therapy
Lipoxins
/ therapeutic use
Lung
/ drug effects
Lung Injury
/ drug therapy
Periodontitis
/ drug therapy
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Respiratory Distress Syndrome
/ drug therapy
SARS-CoV-2
/ pathogenicity
Sepsis
/ drug therapy
Tuberculosis, Pulmonary
/ drug therapy
COVID-19 Drug Treatment
COVID-19
acute respiratory distress syndrome
inflammation resolution
lung injury
specialized proresolving mediators
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
18
08
2020
revised:
08
10
2020
accepted:
12
10
2020
pubmed:
30
11
2020
medline:
18
2
2021
entrez:
29
11
2020
Statut:
ppublish
Résumé
Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long-chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease-19 (COVID-19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.
Identifiants
pubmed: 33249673
doi: 10.1002/biof.1691
pmc: PMC7744833
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Lipoxins
0
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-18Informations de copyright
© 2020 International Union of Biochemistry and Molecular Biology.
Références
Biofactors. 2020 Sep;46(5):766-776
pubmed: 32668503
Int Immunopharmacol. 2013 Oct;17(2):283-92
pubmed: 23816538
FASEB J. 2019 Jan;33(1):909-916
pubmed: 30052486
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Arch Med Res. 2020 Apr;51(3):282-286
pubmed: 32229155
Int J Mol Sci. 2017 Feb 23;18(3):
pubmed: 28241480
Biofactors. 2021 Jan;47(1):6-18
pubmed: 33249673
Nat Rev Immunol. 2016 Jan;16(1):51-67
pubmed: 26688348
Front Immunol. 2018 Oct 16;9:2345
pubmed: 30459754
Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):76-81
pubmed: 31904604
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14983-8
pubmed: 22927428
Crit Care Med. 2014 Apr;42(4):e288-95
pubmed: 24463858
Cancer Metastasis Rev. 2020 Jun;39(2):337-340
pubmed: 32385712
J Immunol. 2007 Jan 1;178(1):496-502
pubmed: 17182589
Mucosal Immunol. 2014 May;7(3):549-57
pubmed: 24064666
Am J Pathol. 2020 Sep;190(9):1782-1788
pubmed: 32650004
FASEB J. 2019 Nov;33(11):13028-13039
pubmed: 31500466
J Allergy Clin Immunol. 2013 Sep;132(3):547-553
pubmed: 23608729
Crit Care Clin. 2020 Apr;36(2):391-399
pubmed: 32172820
Oncotarget. 2017 Dec 14;9(6):7204-7218
pubmed: 29467962
Chem Rev. 2011 Oct 12;111(10):5922-43
pubmed: 21766791
Front Immunol. 2019 Feb 26;10:307
pubmed: 30863409
Oxid Med Cell Longev. 2019 Jun 18;2019:8107265
pubmed: 31316721
PLoS One. 2014 Oct 15;9(10):e108854
pubmed: 25329995
Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):935-40
pubmed: 22215599
Cell. 2012 Feb 3;148(3):434-46
pubmed: 22304914
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Mol Aspects Med. 2018 Dec;64:1-17
pubmed: 28802833
J Immunol. 2003 Dec 15;171(12):6856-65
pubmed: 14662892
Br J Pharmacol. 2008 Mar;153 Suppl 1:S200-15
pubmed: 17965751
Sci Rep. 2017 Dec;7(1):99
pubmed: 28273909
Front Immunol. 2018 Jan 29;9:38
pubmed: 29434586
Mol Nutr Food Res. 2021 Jan;65(1):e1900924
pubmed: 32112513
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):224-233
pubmed: 30528790
J Immunol. 2014 Dec 15;193(12):6031-40
pubmed: 25392529
Thorax. 2002 Feb;57(2):137-41
pubmed: 11828043
Free Radic Biol Med. 2012 Jul 1;53(1):160-71
pubmed: 22580336
Mediators Inflamm. 2016;2016:3798465
pubmed: 28042205
Am Rev Respir Dis. 1992 Jun;145(6):1281-4
pubmed: 1595991
Nature. 2009 Oct 29;461(7268):1287-91
pubmed: 19865173
Am J Respir Cell Mol Biol. 2013 May;48(5):610-8
pubmed: 23470626
Front Immunol. 2020 Apr 28;11:581
pubmed: 32528461
J Exp Med. 2015 Oct 19;212(11):1851-68
pubmed: 26392224
J Periodontal Implant Sci. 2019 Apr 24;49(2):105-113
pubmed: 31098331
Chin Med J (Engl). 2018 Apr 20;131(8):982-989
pubmed: 29664060
Oral Dis. 2019 Jul;25(5):1265-1276
pubmed: 30230662
J Virol. 2010 Aug;84(15):7613-24
pubmed: 20504916
Hum Mol Genet. 2008 Apr 1;17(7):1052-60
pubmed: 18174194
Transl Res. 2015 Jul;166(1):57-69
pubmed: 25655838
J Immunol. 2011 Feb 1;186(3):1735-46
pubmed: 21187448
Int Immunopharmacol. 2019 Nov;76:105877
pubmed: 31522017
Biochimie. 2014 Apr;99:1-7
pubmed: 24262603
Int J Mol Sci. 2020 Feb 28;21(5):
pubmed: 32121251
Infect Immun. 2017 Sep 20;85(10):
pubmed: 28694292
Front Microbiol. 2019 Mar 12;10:358
pubmed: 30915039
Nature. 2012 Apr 25;484(7395):524-8
pubmed: 22538616
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Br J Pharmacol. 2014 Nov;171(22):5011-31
pubmed: 24977655
J Immunol. 2017 Jun 15;198(12):4738-4752
pubmed: 28500069
J Exp Med. 1992 Dec 1;176(6):1703-18
pubmed: 1460427
Mediators Inflamm. 2013;2013:862628
pubmed: 23766562
J Immunol. 2007 Nov 15;179(10):7021-9
pubmed: 17982093
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Int J Mol Sci. 2018 Sep 21;19(10):
pubmed: 30241412
PLoS One. 2011;6(9):e24422
pubmed: 21935407
J Immunol. 2005 Apr 1;174(7):4345-55
pubmed: 15778399
FASEB J. 2018 Sep;32(9):5026-5038
pubmed: 29913556
Sci Transl Med. 2016 Aug 24;8(353):353ra111
pubmed: 27559094
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7971-7980
pubmed: 32205444
J Immunol. 2014 Apr 15;192(8):3765-77
pubmed: 24646745
Am J Respir Crit Care Med. 2017 Sep 15;196(6):713-726
pubmed: 28245134
Cell. 2013 Mar 28;153(1):112-25
pubmed: 23477864
Crit Care Med. 2017 Jan;45(1):58-68
pubmed: 27632672
Front Immunol. 2020 Aug 11;11:1997
pubmed: 32983141
Br J Pharmacol. 2020 Sep;177(17):3898-3904
pubmed: 32557557
Front Pharmacol. 2019 Aug 23;10:938
pubmed: 31507425
Nat Immunol. 2004 Apr;5(4):388-92
pubmed: 15034576
Invest Ophthalmol Vis Sci. 2013 Sep 17;54(9):6269-79
pubmed: 23942967
Am J Respir Cell Mol Biol. 1990 Aug;3(2):113-8
pubmed: 2116155
Biochim Biophys Acta. 2015 Apr;1851(4):496-502
pubmed: 25617737
Int Immunopharmacol. 2019 Sep;74:105694
pubmed: 31226532
Am J Respir Crit Care Med. 2009 Aug 15;180(4):311-9
pubmed: 19483113
J Clin Periodontol. 2019 Oct;46(10):978-990
pubmed: 31339183
Transl Res. 2015 Aug;166(2):111-33
pubmed: 25814167
J Immunol. 2018 Dec 1;201(11):3343-3351
pubmed: 30348736
Br J Pharmacol. 2019 Apr;176(8):1024-1037
pubmed: 29679485
J Immunol. 2007 Mar 15;178(6):3912-7
pubmed: 17339491
Cell. 2010 Mar 5;140(5):717-30
pubmed: 20211140
J Clin Invest. 2005 Jun;115(6):1601-6
pubmed: 15931391
Mol Aspects Med. 2017 Dec;58:44-56
pubmed: 28455109
Pharmacol Ther. 2013 Dec;140(3):280-9
pubmed: 23880288
Chin Med J (Engl). 2018 May 20;131(10):1167-1173
pubmed: 29553051
Oral Dis. 2020 Mar;26(2):429-438
pubmed: 31814225
Front Pharmacol. 2019 Apr 02;10:252
pubmed: 31001110
J Immunol. 2010 Jan 15;184(2):836-43
pubmed: 20007539
Immunology. 2014 Feb;141(2):166-73
pubmed: 24400794
Periodontol 2000. 2020 Feb;82(1):205-213
pubmed: 31850636
Am J Pathol. 2015 Dec;185(12):3189-201
pubmed: 26468975
Physiol Rev. 2018 Jul 1;98(3):1335-1370
pubmed: 29717929
PLoS One. 2013;8(3):e58258
pubmed: 23484005
J Periodontol. 2020 Oct;91 Suppl 1:S19-S25
pubmed: 32441774
Shock. 2011 Oct;36(4):410-6
pubmed: 21701419
Pharmacol Ther. 2019 May;197:212-224
pubmed: 30759375
Clin Sci (Lond). 2017 Aug 24;131(18):2347-2362
pubmed: 28779028
Lab Invest. 2017 May;97(5):543-554
pubmed: 28218740
Clin Transl Sci. 2017 Jan;10(1):28-34
pubmed: 27806191
Int Immunopharmacol. 2018 Mar;56:330-338
pubmed: 29438939
J Adv Res. 2018 Jan 03;11:57-66
pubmed: 30034876
Mediators Inflamm. 2019 Jan 16;2019:2309175
pubmed: 30800000